Access to Drug Treatments

This page has the latest updates about the impact of COVID-19 on access to drug treatments, clinical trials and regulatory authority timetables. For other information on research and drug treatments, please go here.

Some have asked whether patients due for nusinersen treatment should be tested for COVID-19 before they attend hospital. Expert clinicians advise that currently (as of 01/05/2020) they are not asking for patients to be tested, but if unwell (even if not COVID-19 positive) and even more so if COVID-19 positive, they would generally advise to postpone the administration of nusinersen. This may vary – talk with your treatment team if you’re not sure about what’s happening at your centre.

11th June: 

Information Statement from the NHS England Clinical Panel for Nusinersen about Access to the Risdiplam Compassionate Use Programme
 

28th May:

AVEXIS UK UPDATES THE COMMUNITY ON PROGRESS TOWARDS ACCESS TO ZOLGENSMA
 

13th May:

SCHOLAR ROCK REPORTS DELAYS IN INTERIM TRIAL RESULTS DUE TO COVID-19 

7th May: 

REQUEST FOR NICE TO RECONSIDER THE DECISION TO SUSPEND THE APPRAISAL PROCESS FOR RISDIPLAM
 

24th April:

FAQs re Access to Roche’s risdiplam Compassionate Use Programme (CUP) in the UK
 

17th April:

ROCHE UPDATES SMA UK ABOUT THEIR COVID-19 RESPONSE MEASURES AND PRE-APPROVAL ACCESS TO RISDIPLAM
 

7th April:

NICE’s Scoping of Risdiplam Treatment Delayed due to COVID-19
 

6th April:

Information Statement about how Access to Nusinersen Treatment will be Affected by COVID-19 (coronavirus)
 

3rd April:

NICE Confirms Appraisal of onasemnogene abeparvovec (Zolgensma) is not Defined as Therapeutically Critical
 

27th March

ZOLGENSMA: REQUEST TO NICE TO INCLUDE appraisal as a therapeutically critical topic in COVID-19 IMPacted Work Programme
  

20th March

Nusinersen MAA: Statement from NHS England and NICE


16th March

BIOGEN'S STATEMENT RE: CORONAVIRUS (COVID-19) IMPACT on access to nusinersen
 

13th March

ROCHE’S CLINICAL DEVELOPMENT PROGRAMME STATEMENT RE: CORONAVIRUS (COVID-19) IMPACT on risdiplam trials and global access programme